Clinical Gastroenterology and Hepatology
Volume 6, Issue 12 , Pages 1315-1341 , December 2008

A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: 2008 Update

  • Emmet B. Keeffe

      Affiliations

    • Division of Gastroenterology and Hepatology, Stanford University Medical Center, Stanford, California
    • Corresponding Author InformationAddress requests for reprints to: Emmet B. Keeffe, Stanford University Medical Center, 750 Welch Road, Suite 210, Palo Alto, CA 94304-1509. fax: 650-498-5692
    • ,
  • Douglas T. Dieterich

      Affiliations

    • Department of Medicine, Mount Sinai Medical Center, New York, New York
    • ,
  • Steven-Huy B. Han

      Affiliations

    • Division of Digestive Diseases, University of California, Los Angeles, Los Angeles, California
    • ,
  • Ira M. Jacobson

      Affiliations

    • Division of Gastroenterology and Hepatology, Weill Medical College of Cornell University, New York, New York
    • ,
  • Paul Martin

      Affiliations

    • Center for Liver Diseases, University of Miami School of Medicine, Miami, Florida
    • ,
  • Eugene R. Schiff

      Affiliations

    • Center for Liver Diseases, University of Miami School of Medicine, Miami, Florida
    • ,
  • Hillel Tobias

      Affiliations

    • Liver Transplant Service, New York University Medical Center, New York, New York

Full Text Available

  • Purchase this article for  31.50 USD

    Access is available for 24 hours.

    (Login or Register to purchase)

  • Subscribe to this title
  • Claim access now

    Current subscribers


    •  The authors wish to thank Kathy Covino, PhD, for her editorial contributions and assistance in the preparation of the manuscript.

     The authors disclose the following: This algorithm was developed with support by an unrestricted educational grant from Gilead Sciences.

     Dr Keeffe is an employee of Romark Laboratories and has been a consultant for and served on advisory boards for Bristol-Myers Squibb, Gilead, Idenix, Novartis, and Roche. Dr Dieterich has received grant or research support and honoraria from Bristol-Myers Squibb, Gilead, Idenix, and Roche. Dr Han has received grant or research support, served on the advisory boards, and been a member of speakers' bureaus for Bristol-Myers Squibb, Gilead, and Roche. Dr Jacobson has received grant or research support from Coley, Gilead, Globelmmune, InterMune, Ribozyme, Valeant, and Schering-Plough; is a consultant for Anadys, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Coley, Gilead, Globelmmune, Idenix, InterMune, Novartis, Pfizer, Schering-Plough, Valeant, and Vertex; and is on speakers' bureaus for Bristol-Myers Squibb, Gilead, GlaxoSmithKline, and Schering-Plough. Dr Martin has been a consultant, speaker, and investigator for Gilead, Bristol-Myers Squibb, Idenix, Novartis, Roche, and Schering. Dr Schiff has been a consultant to Abbott, Achillion, Bayer, Bristol-Myers Squibb, Cadence, Gilead, GlobeImmune, Idenix, Maxim, National Genetics Institute, Novartis, Ortho-Biotech, Pharmasset, Pfizer, PowerMed Limited, Prometheus, Roche Molecular, Salix, Sankyo Pharma, Schering-Plough, and SciClone; he has research grants and support including clinical trials from Abbott, Bayer, Bristol-Myers Squibb, Coley, Gilead, GlaxoSmithKline, Idenix, Ortho-Biotech, Prometheus, Roche Diagnostics, Roche Molecular, Roche Pharmaceutical, Schering-Plough, SciClone, and Vertex; and he has served on the speakers' bureau or received honoraria from Abbott, Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Idenix, Ortho-Biotech, and Schering-Plough. Dr Tobias has served as a consultant and/or is on speakers' bureaus for Bristol-Myers Squibb, Gilead, Novartis and Roche.

    PII: S1542-3565(08)00853-7

    doi: 10.1016/j.cgh.2008.08.021

    Clinical Gastroenterology and Hepatology
    Volume 6, Issue 12 , Pages 1315-1341 , December 2008